Physician profile
Gloria Cable
NPI 1104480029
$2,032.61
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $719 · 2023: $259 · 2024: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467.44 | 2021-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $249.66 | 2021-2023 | Farxiga |
| Abbvie INC. | $221.24 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.96 | 2021-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2021 | |
| Lilly USA, LLC | $117.17 | 2022-2023 | Mounjaro, Jardiance |
| Mylan Specialty L.P. | $100.81 | 2021-2022 | |
| Amarin Pharma, INC. | $98.44 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $64.13 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $61.26 | 2022-2023 | Verquvo, Steglatro |
| Otsuka America Pharmaceutical, INC. | $52.76 | 2023-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $52.07 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.07 | 2024 | Caplyta |
| Lundbeck LLC | $45.69 | 2024 | Rexulti |
| Amgen INC. | $36.84 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.89 | 2023 | |
| Exact Sciences Corporation | $23.29 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.00 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $13.25 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $12.82 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $11.96 | 2022 | |
| Esperion Therapeutics, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Cable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.